DUBLIN, October 12, 2017 /PRNewswire/ --

The "Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report" report has been added to Research and Markets' offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

The report profiles 24 companies including many key and niche players such as:

• Bharat Serums and Vaccines Limited (India)
• Biotest AG (Germany)
• China Biologic Products, Inc. (China)
• CSL Limited (Australia)
• Grifols, S.A. (Spain)
• Guizhou Taibang Biological Products Co., Ltd (China)
• Hualan Biological Engineering Inc. (China)
• Kedrion S.p.A. (Italy)
• LFB Group (France)
• Octapharma AG (Switzerland)
• Shanghai RAAS Blood Products Co., Ltd. (China)
• Shire plc (Ireland)
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China)
  

Key Topics Covered: 

1. INDUSTRY OVERVIEW
Immunoglobulins to See Steady Growth
Intravenous Immunoglobulin
A Proliferating Biologic
Application Areas
A Brief Review
Market Outlook
Growth Drivers and Market Challenges
Competitive Scenario
Grifols Continues to Consolidate Market Position
Comparison of Select Drugs and Approved Indications
CSL Sees Robust Growth in Immunoglobulin Franchise
Shire Continues to Invest Big in Immunoglobulins
Bivigam Changes Hands Consequent to Unexpected Turn of Events

2. MARKET TRENDS
Strong Demand from Major Indications and Pipeline SCIg Products to Fuel Growth of Immunoglobulins
Increasing Awareness of Primary Immunodeficiency Disease to Drive IVIg Market
The Mainstay of PI Therapy
Subcutaneous IG Formulations Gain Therapeutic Foothold
Hyperimmune Globulin
Taking IVIg Therapy a Step Ahead
Unsuccessful Clinical Trials for Alzheimer's
A major Setback for IVIg Market
Synthetic Replacements to IVIg Therapy
IVIg Therapy
Home-based vs. Outpatient Settings
Per Capita Consumption Rate Varies Across Countries
Favorable Reimbursement and High Usage make US the Largest Consumer
Growing Adoption of Screening Programs to Reduce Usage of Immunoglobulins in the Treatment of SCID
Aging Global Population: Major Opportunity Indicator
Improving Healthcare Expenditure to Foster Growth

3. PLASMA PROTEINS - AN OVERVIEW
Plasma and Plasma Derivatives Continue to Dominate Blood Components Market
Regulations Exercise a Tight Rein over Plasma Therapy & Immunoglobulins

4. THERAPY OVERVIEW
Immunoglobulins Overview
IVIg and SCIg: A Face-off!
Cost of Product and Treatment
Side-Effects
Frequency of Treatment
Safety Considerations
Patient Response to Treatment Varies
Site of Care
IVIg Therapy Introduction
Intravenous Immunoglobulin
Mechanism of IVIg Action
IVIg Dosage and Treatment Response Time
Common IVIg Intravenous Dosing Recommendations by Indication
Complications and Side Effects of Using IVIg
Precautions to be Undertaken
Intravenous Immunoglobulin
Indications
FDA Approved Indications for IVIg
Off-Label Usage of IVIg
Select Off-Label Indications for IVIg
Applications by Medical Specialty
Neurology
Hematology
Immunology
Dermatology
Nephrology, Rheumatology, Ophthalmology, and Other Diseases

5. RECENT INDUSTRY ACTIVITY
LFB Group's 10% IVIg Gains More Approvals in Europe
CSL Acquires Majority Stake in Ruide
Baxter Acquires Claris Injectables
ADMA Biologics Takes Over BTBU
Green Cross Receives FDA Complete Response Letter for IVIG-SN
China Biologic Products Completes Acquisition of Guizhou Taibang
ProMetic Completes Patient Enrolment for Phase III Pivotal IVIG Trial
Kroger Combines Axium Pharmacy and Modern HC
Shire Acquires Baxalta
FDA Accepts BLA for IVIG-SN from Green Cross
Kedrion Bags US Commercial Rights to BIVIGAM
China Biologic Products to Commence Clinical Trials on Next- Gen IVIG Products
FDA Clears ProMetic's IND for IVIg
LFB Obtains Initial Market Authorizations for 10% Liquid IVIg in Europe
Baxter Divests its BioScience Division
Emergent BioSolutions Acquires Cangene
CMS Begins Evaluation of Payment for In-home IVIG Administration

6. FOCUS ON SELECT PLAYERS

7. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 24 (including Divisions/Subsidiaries 32)

• The United States (11)
• Canada (2)
• Japan (1)
• Europe (8)
• France (1)
• Germany (1)
• The United Kingdom (2)
• Italy (1)
• Spain (1)
• Rest of Europe (2)
• Asia-Pacific (Excluding Japan) (9)
• Latin America (1)

For more information about this report visit https://www.researchandmarkets.com/research/z6rgb6/intravenous

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets